Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy
Chemokines can induce chemotactic cell migration by interacting with G protein-coupled receptors to play a significant regulatory role in the development of cancer. CXC chemokine-12 (CXCL12) can specifically bind to CXC chemokine receptor 4 (CXCR4) and is closely associated with the progression of c...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/8/1541 |
| _version_ | 1797408452858871808 |
|---|---|
| author | Ruogang Zhao Jianhao Liu Zhaohuan Li Wenhui Zhang Feng Wang Bo Zhang |
| author_facet | Ruogang Zhao Jianhao Liu Zhaohuan Li Wenhui Zhang Feng Wang Bo Zhang |
| author_sort | Ruogang Zhao |
| collection | DOAJ |
| description | Chemokines can induce chemotactic cell migration by interacting with G protein-coupled receptors to play a significant regulatory role in the development of cancer. CXC chemokine-12 (CXCL12) can specifically bind to CXC chemokine receptor 4 (CXCR4) and is closely associated with the progression of cancer via multiple signaling pathways. Over recent years, many CXCR4 antagonists have been tested in clinical trials; however, Plerixafor (AMD3100) is the only drug that has been approved for marketing thus far. In this review, we first summarize the mechanisms that mediate the physiological effects of the CXCL12/CXCR4 axis. Then, we describe the use of CXCL12/CXCR4 antagonists. Finally, we discuss the use of nano-based drug delivery systems that exert action on the CXCL12/CXCR4 biological axis. |
| first_indexed | 2024-03-09T03:58:43Z |
| format | Article |
| id | doaj.art-a2cb2cb049ca4eaca0ac298d6cd0e424 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-09T03:58:43Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-a2cb2cb049ca4eaca0ac298d6cd0e4242023-12-03T14:16:53ZengMDPI AGPharmaceutics1999-49232022-07-01148154110.3390/pharmaceutics14081541Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer TherapyRuogang Zhao0Jianhao Liu1Zhaohuan Li2Wenhui Zhang3Feng Wang4Bo Zhang5School of Pharmacy, Weifang Medical University, Weifang 261053, ChinaSchool of Pharmacy, Weifang Medical University, Weifang 261053, ChinaSchool of Pharmacy, Weifang Medical University, Weifang 261053, ChinaSchool of Pharmacy, Weifang Medical University, Weifang 261053, ChinaSchool of Pharmacy, Weifang Medical University, Weifang 261053, ChinaSchool of Pharmacy, Weifang Medical University, Weifang 261053, ChinaChemokines can induce chemotactic cell migration by interacting with G protein-coupled receptors to play a significant regulatory role in the development of cancer. CXC chemokine-12 (CXCL12) can specifically bind to CXC chemokine receptor 4 (CXCR4) and is closely associated with the progression of cancer via multiple signaling pathways. Over recent years, many CXCR4 antagonists have been tested in clinical trials; however, Plerixafor (AMD3100) is the only drug that has been approved for marketing thus far. In this review, we first summarize the mechanisms that mediate the physiological effects of the CXCL12/CXCR4 axis. Then, we describe the use of CXCL12/CXCR4 antagonists. Finally, we discuss the use of nano-based drug delivery systems that exert action on the CXCL12/CXCR4 biological axis.https://www.mdpi.com/1999-4923/14/8/1541CXCL12/CXCR4 axischemokinescancer therapynano-based drug delivery system |
| spellingShingle | Ruogang Zhao Jianhao Liu Zhaohuan Li Wenhui Zhang Feng Wang Bo Zhang Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy Pharmaceutics CXCL12/CXCR4 axis chemokines cancer therapy nano-based drug delivery system |
| title | Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy |
| title_full | Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy |
| title_fullStr | Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy |
| title_full_unstemmed | Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy |
| title_short | Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy |
| title_sort | recent advances in cxcl12 cxcr4 antagonists and nano based drug delivery systems for cancer therapy |
| topic | CXCL12/CXCR4 axis chemokines cancer therapy nano-based drug delivery system |
| url | https://www.mdpi.com/1999-4923/14/8/1541 |
| work_keys_str_mv | AT ruogangzhao recentadvancesincxcl12cxcr4antagonistsandnanobaseddrugdeliverysystemsforcancertherapy AT jianhaoliu recentadvancesincxcl12cxcr4antagonistsandnanobaseddrugdeliverysystemsforcancertherapy AT zhaohuanli recentadvancesincxcl12cxcr4antagonistsandnanobaseddrugdeliverysystemsforcancertherapy AT wenhuizhang recentadvancesincxcl12cxcr4antagonistsandnanobaseddrugdeliverysystemsforcancertherapy AT fengwang recentadvancesincxcl12cxcr4antagonistsandnanobaseddrugdeliverysystemsforcancertherapy AT bozhang recentadvancesincxcl12cxcr4antagonistsandnanobaseddrugdeliverysystemsforcancertherapy |